Skip to content

Study · Not a test of the peptide alone · 2007

2 results

[Side effects of treatment with the long-acting gonadorelin agonist triptorelin in a case of paraphilia].

Hoogeveen JH, van der Veer E

Tijdschrift voor psychiatrie1 Jan 2007

PMID17290340 (opens in a new tab)PepBankPUB-17290340
Publisher pageAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone2

In this study, Gonadorelin (GnRH, LHRH) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Gonadorelin (GnRH, LHRH).

  1. 01HumanNot a test of Gonadorelin (GnRH, LHRH) aloneCase report or seriesEfficacy outcome

    In a 35-year-old man with a paraphilia, long-acting triptorelin, a gonadorelin agonist, was followed by reduced preoccupation with sexuality.

    In plain wordsIn one man with a paraphilia, the long-acting drug triptorelin was followed by less preoccupation with sexuality.

    Peptide
    Gonadorelin (GnRH, LHRH)
    Outcome
    DecreasePreoccupation with sexuality
    Study

    n = 1

    Outcome group
    Sexual function · Reproductive and sexual health

    Source sentences

    Summary
    The desired result was reduced preoccupation with sexuality
    1 context sentence
    Summary · context
    A 35-year-old man with a paraphilia was treated with long-acting gonadorelin.

    In this study, Gonadorelin (GnRH, LHRH) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Gonadorelin (GnRH, LHRH).

  2. 02HumanNot a test of Gonadorelin (GnRH, LHRH) aloneCase report or seriesSafety outcome

    In a 35-year-old man with a paraphilia, long-acting triptorelin, a gonadorelin agonist, was followed by a serious amount of bone loss.

    In plain wordsIn one man with a paraphilia, the long-acting drug triptorelin was followed by serious bone loss.

    Peptide
    Gonadorelin (GnRH, LHRH)
    Outcome
    DecreaseBone loss
    Study

    n = 1

    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    there were various side effects including a serious amount of bone loss
    1 context sentence
    Summary · context
    A 35-year-old man with a paraphilia was treated with long-acting gonadorelin.

    In this study, Gonadorelin (GnRH, LHRH) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Gonadorelin (GnRH, LHRH).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    21 Oct 2026, 18:59 UTC

    Study data updated · source update from Europe PMC

  2. Version 2

    13 Oct 2026, 21:44 UTC

    Study results updated

  3. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.